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ABSTRACT  
Introduction: Lupus Nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE) with a significant 
prognostic impact. Over a prolonged course, an exhaustion of treatment alternatives may occur and further 
therapeutic options are needed. B- cells play a pivotal role in disease pathogenesis and represent an attractive 
therapeutic target. 
Areas covered: This review provides an update regarding targeting B-cells cell in LN. The rational for this approach, as 
well as currently available and future targets are discussed.  
Expert commentary: Despite its wide clinical use and the encouraging results from retrospective studies, a role of 
rituximab in LN has not been prospectively confirmed. Trial design methodologies as well as intrinsic limitations of this 
approach may be responsible and rituximab use is currently limited as a rescue treatment or in settings where a 
strong steroid sparringsparing effect is warranted. Despite belimumab now being licensed for use in SLE, the evidence 
in LN is weak although prospective trials are on-going. The combination of different targeted approaches as well as a 
focus on new clinical end-points may be strategies to identify new therapeutic options. 
 
KEY WORDS:  
Auto-antibodies, Belimumab, B-cells cell, Lupus, Lymphocytes, Nephritis, Rituximab. 
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1. INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by a wide spectrum of organ 
involvement and disease severity; renal involvement (lupus nephritis, LN) may occur in up to 40% of SLE patients (1).  
SLE glomerulonephritis is the hallmark of the immune complexescomplex disease and it is the most frequent severe 
manifestation of LN. Among all autoantibodies, anti-dsDNA plays a central role; they are in fact the moremost 
represented among the ones eluted from kidney biopsies (2) and may act as clinical biomarker (3). Despite this, they 
account for only 10-20% of the total auto-antibodies (2), with several others likely to play an important role including 
anti-C1q (4).  
As precursors of autoantibody producing cells, B- cells are considered central in LN pathogenesis, however. However, 
this is only one of their several roles as suggested by the observation of the lack of development of LN in a murine 
models knocked out formodel carrying mutant B- cells despite the presence of autoantibodiesunable to secrete 
immunoglobulins while still expressing them on the surface (5); interaction with T-cells and cytokine production are 
other essential activities (6, 7). Interstitial nephritis is common in LN as unique manifestation of renal disease or in 
association with glomerulonephritis; interestingly SLE interstitial nephritis is usually characterized by an infiltrate rich 
in T and B- cells sometimes organized in aggregates (8, 9) or even germinal center-like structures with evidence of 
local autoantibody production (9). Tubulointerstitial inflammation is particularly relevant in defining long-term 
prognosis of LN patients and is correlated with the risk of end-stage renal disease (10) .The prompt diagnosis and 
treatment of LN has a positive impact on survival as well as on risk of end stage renal disease, however its chronic and 
relapsing course poses several challenges to the overall management.  Induction and maintenance of remission are 
key phases of the staged approach to LN and the identification of the right balance between disease activity, organ 
damage and degree of immunosuppression is central (11, 12). Corticosteroids alone are not sufficient in the treatment 
of LN and the association with immunosuppressive drugs is therefore necessary (13); although long term efficacy is 
well established for cyclophosphamide based regimen, mycophenolate mofetil has shown similar effectiveness at 
least in short and medium term trials with a more favorable adverse event profile (14).  
The availability of biologics with molecular targets is therefore of interest and among several possible targets, the B-
cells cell compartment has strong biological rationale. However, evidence supporting the clinical use of available B cell 
therapies in LN is lacking.  
In this paper we discuss the rationale, the current role as well as future prospective of a B-cells cell targeted approach 
in LN. 
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 4 
 
2. ANTI-CD20 APPROACH AND RITUXIMAB 
CD20 is a B-cell membrane specific antigen involved in B-cell differentiation as well as B – T-cell stimulation. This 
antigen is broadly expressed by every lineage of B-cells with the exception of pro-B lymphocytes and plasma –cells 
(13).  
On the basis of the central role of B-CD20 is a B cell membrane specific antigen involved in B cell differentiation as well 
as B – T-cell stimulation. This antigen is broadly expressed by every lineage of B cells with the exception of pro-B 
lymphocytes and plasmacells (15).  
On the basis of the central role of B cells in SLE pathogenesis and of the results of the effectiveness of this approach in 
other autoantibody mediated diseases (14, 1516, 17), anti-CD20 antibodies have been employed in SLE. 
Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that was approved in 1997 for the treatment of Non-
Hodgkin Lymphoma with its use progressively extended to different autoimmune diseases, such as rheumatoid 
arthritis and ANCA-associated vasculitis. RTX is a type I monoclonal antibody and its action relies on the ability of 
redistributing CD20 into lipid rafts and the development of antigen-antibody complexes required to induce CD20+ B-
cells cell death through three mechanisms: complement dependent cytotoxicity (CDC), antibody dependent 
cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) (1618, 19). A further possible mechanism 
has been described, that involves direct cell death through activation of pro-apoptotic intracellular signaling although 
this mechanism seems more relevant for type II anti-CD20 antibodies that act without redistributing CD20 into lipid 
rafts (17, 1820, 21). The first retrospective study published in 2002 by David Isenberg's group involved six patients 
with SLE and RTX was co-administered with cyclophosphamide: a reduction of the disease activity score used (British 
Isles Lupus Assessment Group, BILAG) from 14 (range 9-27) to 6 (range 3-8) was observed as well as improvement of 
some biomarkers (overall increase of the C3 levels, in some patients reduction of the anti-dsDNA levels); in two 
patients affected by LN a reduction of the protein-to-creatinine ratio was also described (1922). After this study, six 
retrospective and prospective surveys including more than fifty patients exploring the effectiveness of RTX in SLE and 
LN were identified (20-2523-28) (Table 1). In all the studies RTX showed overall efficacy in disease control and, where 
explored, in allowing steroid sparringsparing. The renal response was typically positive and the adverse eventsevent 
rate was relatively low, especially in the context of a population mainly characterized by a relapsing course of the 
disease and exposure to several immunosuppressive drugs. Only one study (2326) reported the outcome of four 
patients treated with pre-emptive multiple administrations of RTX; interestingly, no flares were observed in this 
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 5 
population during a follow-up of 22 ± 9 months. A larger cohort of LN patients with relapsing or refractory disease, 
were studied by pooled data analyses of 164 patients (99 obtained via the UK-BIOGEAS registry and 65 via the review 
of other original articles already published) with LN treated with RTX: in keeping with the reports discussed in Table 1 
a positive response rate was observed in 67% of the population at 6 and 12 months with improvements in proteinuria 
(4.41 g baseline vs 1.31 g post therapy, p=0.006) and serum albumin level (28.55 g baseline vs 36.46 g post therapy, 
p<0.001) (2629). 
The good results observed in the retrospective reports warranted prospective randomized controlled trials (RCTs) for 
confirmation. Two main RCTs have been published in 2010 and 2012: EXPLORER and LUNAR with only the latter 
including patients with LN (27, 2830, 31). Surprisingly, both failed the primary outcome (29); Table 2 summarizes the 
main characteristics of these studies.(32); Table 2 summarizes the main characteristics of these studies. Trials designs 
issues may have contributed to the negative results, especially the use of a background corticosteroid and 
immunosuppressive therapy in both arms, the selection of non-refractory cohorts, relatively short follow-up time, 
patients’ selection and no inclusion of the corticosteroid dose tapering among the parameters to assess the response 
to therapy. Despite the failure to demonstrate clinical benefit, both trials found RTX effective in reducing anti-dsDNA 
levels and improving complement levels. 
Despite the positive results of the retrospective studies and continuing physician and patient interest in the use of 
RTX, B cell depletion is currently only recommended as a rescue treatment for patients that are refractory to first and 
second line induction-maintenance approaches or in particular settings where a strong steroid sparringsparing 
approach may be required  (25, 3028, 33). 
 
2.1 Main limitations of B-cells cell depletion therapy with Rituximab. 
The lack of clear evidences supporting the use of RTX in SLE and LN may not only be due to issues related to trials 
design but also to intrinsic limitations of a B-cells cell depletion approach through anti-CD20 antibodies as well as 
intrinsic SLE limitations. 
SLE has a huge variability in terms of clinical profiles and a B-cells cell depletion approach might be effective only in 
specific subsets of the disease yet to be identified. RTX has typically been given in addition to an immunosuppressive 
in LN trials, most commonly mycophenolate mofetil. The BELONG trial (34) tested ocrelizumab in addition to either 
mycophenolate or cyclophosphamide and a larger treatment effect was noted on a cyclophosphamide background, in 
part due to a lower placebo response rate with cyclophosphamide. There are theoretical advantages to the 
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 6 
combination of RTX with both mycophenolate or cyclophosphamide by targeting B cells at different levels. 
Interestingly, the combination of RTX and cyclophosphamide has shown in small studies positive results (35); although 
the safety profile does not allow a prolonged cyclophosphamide administration, the combination of these drugs at 
least in some stages might lead in subgroups of patients to advantages in the disease control. 
Moreover, B- cell depletion is not selective leading to the targeting also of subsets that may be of help in controlling 
autoimmunity (such as regulatory B- cells, B-regs) sparing at the same time other subsets able to produce pathogenic 
autoantibodies (namely plasma-cellsplasmacells). 
Several studies focused on the use of RTX in autoimmune diseases have shown that the longer duration of B- cell 
depletion achieved, the better is the clinical response to the drug (3136); howeverdespite also in SLE a deep depletion 
has been found as associated to clinical response (37), the proportion of patients achieving B-cells depletion after 
RTXit is lower and the timing of B cell repopulation is quicker (32).(38). Several factors have been considered 
responsible, such as, the presence or development of human anti-chimeric antibodies (HACAs) (33, 3439, 40) as well 
as differences in terms of RTX clearance (3541) as a consequence of a different immunoglobulin metabolism.  
It should also be considered that, although we usually assess B- cell depletion in the circulating compartment, this 
might not reflect what is happening in inflamed tissues. Tissue resident CD20+ B- cells may be more resistant to RTX 
(3642) as a consequence of a low tissue penetration of the drug or local survival factors including cell to cell contact 
and B cell stimulating cytokines; interestingly it has also been described in ABO-incompatible kidney transplant 
patients who received a single RTX infusion, that the proportion of CD19+ B- cells in lymph nodeslymphnodes did not 
differ to the ones of untreated controls and their phenotype was more often compatible with that of switched 
memory B- cells (IgD-CD27+), the phenotype moremost represented in peripheral blood of active SLE and not 
detectable in SLE patients in remission once treated  (37, 3843, 44). 
Moreover, as already discussed, RTX is a type I monoclonal antibody and its action involves the gathering of antibody-
antigen complexes into lipid rafts of the cells: this facilitates ADCC and CDCC, but induces internalization and 
inactivation of the drug (39, 4045, 46). Internalization may also be consequence of other factors such as the surface Fc 
gamma receptor (FcgR) IIb  (41, 4247, 48).  
Many other factors have been proposed to play a role such as low complement levels and the presence of anti-C1q 
antibodies as factors impacting negatively on CDCC; moreover, the genetically determined variability of FcgR affinity 
for the Fc portions of antibodies (43, 4449, 50) as well as hypergammaglobulinemia might cause an alteration of the 
phagocytosis/ADCC through low affinity for ligand/ligand competition (1720). Field Code Changed
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 7 
Newer anti CD20 antibodies include the fully humanized type I (ocrelizumab and ofatumumab) or type II antibodies 
(obinutuzumab). For ocrelizumab a randomized controlled trial in LN (BELONG) was suspended due to excessive 
adverse events (4534) although the drug seems to be effective especially in cases refractory to RTX (51), whereas for 
ofatumumab there is a limited, although positive, clinical experience on five patients with SLE and LN (46, 4752, 53) 
with further data required before its use may be considered in routine clinical practice. Regarding obinutuzumab 
(17)(20), a randomized control trial is now running and it will provide important information regarding the feasibility 
and safety of its use in SLE (NCT02550652). Of note, both LUNAR with RTX and BELONG with ocrelizumab found 
similar increases in renal response rates of 11-12% when compared to placebo (4534). These were lower than the 
predicted response rates to show statistical superiority but of a similar order to that found in the belimumab trials, 
although using a different end-point. The latter studies had very much larger sample sizes and consequently met their 
end-points and were regarded as positive studies. 
 
3. MODULATING B- CELL SURVIVAL  
A suitable alternative to B-cells cell depletion may be the modulation of B-cells cell survival. In SLE B- cells are 
characterized by a longer lifespan, an anti-apoptotic molecular profile as well as a lower threshold for activation 
compared to healthy patients (48).(54). Acting on factors inducing these characteristics with the aim of restoring a 
physiological profile may improve disease control. 
A central role in driving SLE B- cell hyperactivity is accounted by two members of the Tumor Necrosis Factor (TNF) 
ligand superfamily (TNFSF13): the B- cell Activating Factor (BAFF, also known as Blys or TNFSF13B) and A Proliferation-
Inducing Ligand (APRIL).  
BAFF and APRIL actions are mediated via three receptors: the Transmembrane Activator and Calcium-Modulator and 
Cytophilin Ligand Interactor (TACI), the B- cell Maturation Antigen (BCMA) and the B-Cell cell Activating Factor 
Receptor (BR3) (4955).  
B- cells at different maturation stages express different receptors with TACI mainly promoting T-cell independent 
antibody responses as well as B- cell regulation and immunoglobulin isotype switching, BCMA mainly promotes 
plasma-cell survival and BR3 accounts for immature B- cell survival and maturation.(5056) . 
The rationale for targeting these pathways is provided by the observation that both BAFF and APRIL levels are 
increased in SLE patients (51-5357-59); moreover, mice models characterized by BAFF over-expression develop an SLE-
like disease (5460). Furthermore, BAFF levels have been consistently described as increased after B- cell depletion via 
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 8 
anti CD20 approaches (55, 5661, 62) and it has been described as higher in SLE patients experiencing a relapse after 
RTX administration when compared to patients who maintain disease remission (5561); this has been also leading to 
the hypothesis that BAFF may play a role, at least of some degree, in limiting the effectiveness of B- cell depletion. 
Whether the BAFF increase reflects simply the loss of BAFF receptors, only found on B cells, or implies a disease 
stimulating effect of RTX is unclear and there is also evidence that a high BAFF level influences the returning B cell 
repertoire towards a more autoreactive phenotype (5763). 
Since the early 2000s drugs targeting BAFF and APRIL have been studied in SLE. Atacicept is a recombinant fusion 
protein including the extracellular domain of the TACI receptor joined to a human IgG1 Fc domain (5864) that has 
been tested in moderate-severe SLE in a phase II trial, this study was terminated prematurely due to safety concerns 
(59, 6065, 66). Efficacy was observed in the arm treated with the higher dose of the drug tested (150 mg-arm) 
although the same group experienced two fatal infections. The on-going ADDRESS II trial (NCT02070978) might be 
able to shed more light on the possible role of this drug. A LN trial was terminated due to the occurrence of 
hypogammaglobulinaemia and infection in atacicept treated patients, when administered in addition to 
mycophenolate mofetil and high dose corticosteroid (6167). 
More evidence are available for the anti-BAFF humanized monoclonal antibody belimumab: BLISS-52 and BLISS-76 are 
two large phase III multinational trials, which showed efficacy for belimumab in SLE in reducing disease activity as 
defined by the SLE responder index, a composite of disease activity scores (Table 3) (62, 6368, 69); these data found a 
favorable long-term safety profile (6470) and resulted in this monoclonal antibody being the first biological drug 
approved for the use in SLE in several countries. However, the evidence for its efficacy is at the moment mainly limited 
to muscoloskeletal and mucocutaneous subsets of the disease and it is still uncertain whether it may have a role also 
in LN (65).(71). Interestingly a post-hoc analysis of the pooled cohorts of the BLISS trial showed a signal toward a 
potential role for belimumab in improving some renal outcomes with the limitation of both trials excluding patients 
with acute renal activity at the moment of the enrollment (6672). Retrospective case reports seem to support the 
hypothesis for a role of belimumab in LN (67, 6873, 74) , however it will be the BLISS-LN study (NCT01639339), a 
phase III randomized control trial, the one able to confirm this hypothesis. 
Two other anti-BAFF drugs have shown signals for a potential role in SLE: the monoclonal antibody Tabalumab and the 
fusion protein Blisibimod. (75, 76). Despite a signal for the latter in terms of proteinuria reduction, both have now 
been abandoned and no further studies are ongoing at the moment.    
Tabalumab efficacy has been explored in two phase III randomised controlled trials, ILLUMINATE-1 and ILLUMINATE-2 
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 9 
(69, 70) showing a signal for efficacy only in the latter, although limited to the group of patients receiving the drug at 
the higher dose (120 mg every 2 weeks). A post-hoc analysis of these two studies failed in identifying any effect on 
renal outcomes (71). 
Blisibimod appears to be a candidate of great interest: it is a fusion protein characterized by high potency (72) with 
the highest affinity among the group of BAFF inhibitors (73). Moreover, it has a long serum half-life (8-10 days) and 
binds BAFF in both its form (soluble and already membrane-bound) (73). 
Blisibimod efficacy has been tested in a phase 2b study (PEARL-SC), conducted on 547 SLE patients with a 
SELENA/SLEDAI score >6 where a profile for better response compared to placebo was identified in the group treated 
with the higher dose of the drug; interestingly a significant variation in terms of proteinuria compared to placebo was 
observed (74). A phase III trial (CHABLIS-SC1, NCT01395745) terminated early due to a lack of efficacy and further 
development of blisibimod for SLE abandoned. 
 
4. OTHER B- CELL TARGETED THERAPY 
4.1 Modulating B-cells cell response  
B- cell receptor (BCR) signalling, as well as its intracellular transduction via s cond messengers, is increased in SLE (75, 
7677, 78) representing therefore a target of potential interest.  
The inhibitory transmembrane protein CD22 is a member of the immunoglobulin superfamily that recognizes sialic 
acid-containing ligands; it is expressed on different lineage of B- cells with the exception of plasma-blastsplasmablasts 
and plasma-cellsplasmacells (77).(79). Its mechanism of action is not fully understood but for sure it is active at 
different levels: following BCR stimulation, CD22 gets activated through a phosphorylation process mediated by Lyn, a 
tyrosine kinase induced by BCR itself, in a feed-forward cycle (78).(80). Once active, CD22 induces intracellular 
signalling resulting eventually in BCR dephosphorylation and inhibition (7981). Interestingly, CD22 mechanisms of 
action appear to be various including indirect interaction with other intracellular signalling pathways such as the ones 
mediated by CD40 and Toll-like Receptors as well as clustering with the BCR component CD79a (8082). CD22 is 
therefore central in setting the B- cell threshold of activation. 
Epratuzumab is a humanised anti-CD22 monoclonal antibody that acts by inducing CD22 
phoshporylationphosphorylation as well and shifting into lipid rafts, this reducesthus reducing intracellular BCR 
signalling. Internalisation of CD22, and therefore also of the BCR component CD79a, is another proposed mechanism 
of action of epratuzumab (81) as well as a partial B-cells depletion involving mainly the subset of naive B-cells (82). 
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Effectiveness for this drug in SLE has been proposed from two phase IIHowever its clinical trials (ALLEVIATE 1 and 2) 
(83, 84) but efficacy has not been confirmed according to the preliminary results of two still unpublished phase III 
randomised control trials (EMBODY-1 and 2) and the drug has been at the moment abandoned (8583). Despite that, 
CD22 remainremains a target of great interest that may be considered for future therapeutic approaches.  
 
4.2 Targeting Intracellular pathways 
One of the main limitations of aiming for cytokines, or their receptors, is the presence of physiological mechanisms 
acting at the limitation of the “single targets approaches” such as the redundancy of the stimulus as well as the 
molecules’ internalization once bound to their cellular surface targets. Acting directly on the intracellular signals, and 
therefore on the downstream part of the activation cascade, might therefore represents a way to avoid the downsizes 
of the single target approach. 
The Bruton’s tyrosine kinase (BTK) is a key member of the BCR and FcgR signaling cascade, inducing the stimulation of 
B-cells cell survival, differentiation as well as setting the activation threshold and inducing the antibody production 
(86-8984-87). BTK blocking has been explored in several SLE mouse models with signals of effectiveness in terms of 
preventing and treating renal disease (90-9488-92). 
The Spleen Tirosine Kinase (SYK) is a kinase directly activated by the Immunoreceptor tyrosine-based activation motif 
(ITAM) sequence of BCR co-receptors as well as of other immune and non-immune related receptors such as the T-cell 
receptor (TCR) and FcgR. SYK has a central pathogenic role in different autoimmune diseases and malignancies (95) as 
well as in glomerulonephritis.(93) as well as in glomerulonephritis. A retrospective study on 120 kidney biopsies of 
patients with glomerulonephritis showed that SYK expression was increased in proliferative and crescentic 
glomerulonephritis and correlates with the presenting serum creatinine as well as histological signs of disease activity; 
interestingly, in the subgroup of LN, SYK showed also a role as biomarker being higher in patients that achieved 
complete remission at 6 months (9694). SYK inhibitors, such as, fostamatinib, seem an attractive and available option 
for autoimmune diseases in general and for kidney involvement of autoimmune diseases in particular (9795). A role in 
LN has been shown in pre-clinical studies on mice; interestingly, the use of this drug was not associated to reductions 
of anti-dsDNA titers confirming a downstream mechanism of action (98, 9996, 97). Data regarding fostamatinib in 
human SLE are not available although the encouraging results in terms of potential efficacy and safety in rheumatoid 
arthritis suggest that this is a treatment worth exploring (100).(98).  
The Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) path has been recently tested in SLE and 
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LN in two studies. There are four members of the JAK family and this path is particularly active in cytokine receptor 
signaling influencing DNA transcription and protein synthesis. The first study explored CP690550 showing in murine 
models improvement of proteinuria, renal function as well as histological lesions of the kidneys; interestingly a 
reduction of glomerular deposition of anti-dsDNA, of C3 and IgG was observed as well as a reduction in kidney gene 
expression of inflammatory cytokines (10199). Another potential candidate acting on the JAK-STAT cascade is 
Tofacitininb characterized by promising results in terms of improvement of the nephritis in mice models (102100). 
 
4.3 Modulating B-T cell interactions 
T-cells play a detrimental role in driving and boosting autoimmune responses. Several reports have described 
dysfunction of the T-cell compartment in SLE mainly involving Follicular Helper T-cells (Tfh), Regulatory T-cells and 
Th17 (103) . 
T cells play a detrimental role in driving and boosting autoimmune responses. Several reports have described 
dysfunction of the T cell compartment in SLE mainly involving Follicular Helper T cells (Tfh), Regulatory T cells and 
Th17 (101) . 
Tfh are attractive targets having a central role in conditioning germinal centers, in facilitating expansion of 
autoreactive clones and in stimulating differentiation of B- cells into plasmablasts and plasma-cellsplasmacells 
(104).(102). Tfh actions are mediated via cytokine secretion as well as via B-T cell interactions; the latter is allowed 
through several co-receptors, such as CD40-CD40L (CD154), OX40-OX40L, ICOS-ICOSL, CTLA4/CD28-CD80/CD86.  
CD40L is an important co-stimulatory molecule that is up-regulated in SLE, with higher levels of its soluble form 
described as well in this disease (103-105-107), and seem to correlate with disease activity in mice models (108, 
109106, 107); moreover, a single nucleotide polymorphisms (SNP) of CD40 have been associate with disease 
susceptibility (110108). The inhibition of the CD40-CD40L interaction seems a reasonable target and has proven to be 
effective in preventing disease in murine models (111, 112109, 110).  A phase II trial of a CD40L inhibitor (BG9588) in 
lupus nephritis showed a signal in terms of immunological benefit in the patients treated (reduction of the anti-dsDNA 
antibodies, increase of C3 concentrations, reduction of the hematuria); however, the trial was stopped due to safety 
concerns related to a high incidence of thromboembolic events (113111). This was caused by the occurrence of CD40L 
on platelets with Fc mediated platelet cross-linking caused by the therapeutic antibody. Encouraging results in terms 
of safety have now been described with a PEGylated anti-CD40L Fab' fragment (CDP7657) from a phase I study (114, 
115112, 113) suggesting that inhibition of this pathway remains a possible therapeutic target in SLE. An alternative is 
Field Code Changed
Formatted: Level 1
Page 11 of 52
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 12 
to target CD40 and this is being pursued by BI655064, an anti-CD40 monoclonal antibody in a Phase II LN trial 
(NCT02770170).  
CTLA4 is a surface molecule with inhibitory functions competing with the activating surface protein CD28 for the 
binding of CD80/86. A CTLA4-Ig (abatacept) has shown efficacy in patients with non-severe granulomatosis with 
polyangitiis (GPA) (116114). The rationale for targeting this pathway in SLE has been developed from mice models 
where a CTLA4-Ig approach displayed effectiveness in preventing disease onset (117115) or in reducing signs of 
activity in LN when used in combination with cyclophosphamide (118).(116). However, a phase IIb randomized 
controlled trial in non-severe SLE patients (119) and a phase II/III trial in 298 patients with LN failed in meeting the 
primary end-points although a benefit in terms of reduction of anti-dsDNA titre, improvement of C3 and C4 levels as 
well as proteinuria was observed (120). More recently no beneficial effects of abatacept were found in the ACCESS 
trial when added to a background of cyclophosphamide and corticosteroids although a greater effect of 
abataceptdespite effectiveness on anti-dsDNA and complement levels was seen compared with placebo, no beneficial 
clinical effect has been so far shown (121117). 
 
4.4 Proteasome inhibitors 
Proteasome inhibitors are an emerging class of drugs targeting mainly plasma-cells. Among proteasome inhibitors, 
bortezomib is the first one employed in clinical practice with indication at the moment for multiple myeloma. The 
mechanism of actions of this class of drugs is the inactivation of the Nuclear Factor kappa-light chain enhancer of 
activated B-cells cell (NfkB) process eventually able to induce apoptosis (122).(118). Since the high rate of protein 
synthesis typical of plasma-cells, these are very sensitive to the effects of this drug. For proteasome inhibitors also a 
role in reducing the interferon (IFN) path activation as well as IFN production has been proposed as further 
mechanism of action (123119). 
Due to encouraging results for the use of bortezomib in mice models of SLE and LN (124-126120-122) this drug has 
been tested also in humans in a study involving 12 patients with benefits in terms of reduction of the autoantibody-
producing plasma cells, IFN pathway activation and, more significantly, also in terms of clinical activity of the disease 
(127123). The use of bortezomib was however associated to a reduction of protective IgG levels and necessity of 
withdrawing the treatment in seven patients due to adverse events. Interestingly, in murine models a quick 
reconstitution of the plasma cells pool have been observed once the treatment is stopped (128124) and a role for co-
administration of B-cells cell depleting treatment has been proposed as strategy for delaying plasma-cell 
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reconstitution after depletion (128124). An oral proteasome inhibitor, ixasomib with a more favourable safety profile 
is in clinical trials in LN (NCT02176486). 
 
5. CONCLUSIONS 
SLE and LN are chronic diseases that often feature a long disease course with large variability in disease extent and 
severity. First and second line approaches are not infrequently exhausted in a single patient clinical history and newer 
options are required for disease management. The toxicity of current regimens and their associated serious adverse 
event rates directly worsen patient outcomes and safer therapies allowing lower corticosteroid dosing are needed. 
The targeting of B-cells cell is supported by our understanding of pathogenesis, and RTX and belimumab have entered 
routine use in carefully defined scenarios where standard therapies are failing. The uptake of RTX has affected by the 
imbalance between positive retrospective cohort studies in largely refractory patients, and the negative results of the 
two randomised trials. Belimumab has obtained registration for use in SLE although the signals for its utility in LN are 
still weak and its role at the moment is limited to non-renal SLE; more information will be provided after a prospective 
trial in LN now ongoing (NCT01639339).  
Several targets of the B-cells cell biology have been identified and for most of them, despite good preliminary results 
in phase II trials and pre-clinical models, no confirmation has been so far observed in phase III studies.  
 
6. EXPERT COMMENTARY  
SLE is a disease with a complex and still partially unknown biology. The success of the conventional 
immunosuppressive approaches may be due to their low specificity characterized by a widespread effect on the 
immune system; more selective approaches, although potentially of great interest and safer, may allow only partial 
benefits due to the lack of inhibition of alternative pathways not known. Based on this rationale, combining different 
biologics may allow an increase in terms of efficacy; however, such approaches need to be tested carefully considering 
concerns in terms of safety. The most obvious approach at the current stage, would be the combination use of RTX 
and belimumab: B- cell depletion via RTX is in fact characterized by a rebound of BAFF levels which might explain, at 
least in some settings, the lack of efficacy. Preliminary results of subsequent therapy with RTX and belimumab are 
encouraging (129, 130125, 126) and prospective trials are now on-going (Table 4). Furthermore, RTX B- cell killing will 
be potentiated by BAFF blockade. Two trials are studying this approach, CALIBRATE IN LN, and BEAT-LUPUS in non-
renal SLE (Table 4). 
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Another issue related to RTX, although potentially characteristic of other biologics as well, is that the lack of efficacy 
may be a consequence of the mode of administration. We know from experience in other autoimmune diseases that 
retreatment with RTX may improve remission rates as well as prolonging the time to relapse when compared to a 
single course of the drug although, eventually, at the drug withdrawn the relapse rate remains high (131127). 
Moreover, alternative trial designs or the definition of new end-points may facilitate demonstration of drug 
effectiveness: on average the studies published so far are designed to show a superiority or a non-inferiority of a 
tested drug compared to the standard of treatment, usually with an add-on philosophy to what considered the 
standard of care. However, alternative end-points may be of interest such as benefits in terms of tolerability, safety 
and adverse events rate of a new approach compared to standard of treatment despite similar efficacy. The ongoing 
RITUXILUP (Table 4) (NCT01773616)In diseases characterized by a chronic relapsing course, frequent treatment 
changes or dose adjustments are required. In this context the efficacy of a new drug may not necessarily be shown 
only via a greater clinical benefit when added to the standard of care. Of note, clinical trials are usually characterized 
by a relatively short follow-up and an intervention that is lacking impact during the explored time spam might 
however unveil significant outcomes in the long term. In the everyday clinical life the standard of care may sometimes 
not be employed, not tolerated at full dose, refused by the patient or even ineffective. The design of classical clinical 
trials does not take into account this flexibility and may lead to the abandon of potentially useful drugs. Alternative 
end-points may be taken into account in order to provide the clinical community with as many options as possible. We 
should therefore seek for non classical clinical trial designs able to overcome these limitations: examples of alternative 
strategies might include aiming at showing the ability of a new add-on treatment in allowing a quicker and aggressive 
drug sparing effect; a better clinical and safety profile in contexts where an optimal dose of the standard of care may 
not be employed; a better safety or burden of damage in longer follow-up time. Studies with different end-points may 
be characterized by more difficulties in terms of recruitment and may benefit from the use of alternative strategies of 
enrollment or treatment allocation including for example adaptive approaches. An example might be the ongoing 
RITUXILUP (Table 4) (NCT01773616) that is exploring whether the combination of RTX and mofetil mycophenolate 
(MMF) may allow sparing steroids.  
SLE is a complex disease and LN is its most severe manifestation. Research aimed at the identification of new 
therapeutic targets or biomarkers able to perform effective patient stratification is a high priority task in the research 
agenda in order to increase our therapeutic options. Moreover, alternative trials design should be developed in order 
to identify, among all the possible therapeutic targets, the ones that may have a role in the management of this 
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 15 
autoimmune disease. 
 
7. FIVE YEARS VIEW 
Despite significant research efforts in the field of pathogenesis and drug development, no major changes have 
occurred in the management of LN. We do know that MMF and cyclophosphamide appear equal alternatives as first 
line approaches as induction (132128) and that azathioprine, MMF, and in some settings, methotrexate may be useful 
for the maintenance stage. Steroids are the cornerstones of the treatment, playing a central role in all phases as well 
as for the management of minor systemic flares. In this picture is now relatively well established the use of RTX as 
third line agent for both relapsing-refractory SLE and LN. Moreover belimumab is now approved for the management 
of SLE with its use mainly limited at the moment to the mucocutenous and articular manifestations. 
The studies published so far taught us that the heterogeneity of SLE manifestation and population, as well as the 
complexity of the disease, may allowcause difficulty in the identification of a “superiority” or of a “non-inferiority” 
profile for new drugs when compared to an optimal standard of care. We feel that in the next years the trial designs 
will switch to the identification of different end-points such as tolerability, safety and ability of a drug sparringsparing 
effect for the treatment tested.  
The future will probably see also testing different combination of biologics and targeted therapy in order to allow a 
potential increase in efficacy of the intervention proposed. This will need to happen under strict monitoring from the 
safety point of view.  
Beside B- cells, very promising are the preliminary results of targeting the interferon pathway (133, 134129, 130) but 
we do feel there may be in the short-term more interesting therapeutic options. Complement plays a central role in 
SLE and LN pathogenesis and several complement blockade molecules are now available (135131). However, no trials 
are on-going to test effectiveness of this approach in SLE. Interestingly, complement is also detrimental forcrucial in 
mediating the action of several monoclonal antibodies and will be of great interest to see the consequences of 
combining anti complement drugs and other monoclonal antibodies.   
 
8. KEY ISSUES 
• B- cells play a central role in the pathogenesis of SLE and LN therefore representing a therapeutic target of 
interest. 
• Rituximab is an anti-CD20 monoclonal antibody for which retrospective studies and clinical practice have 
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shown efficacy in SLE and LN; prospective trials failed in confirming this although trial design issues, intrinsic 
limitation of both prospective studies in SLE and of an anti-CD20 approach may have had a role in these 
negative findings. 
• Belimumab is an anti BAFF monoclonal antibody registered for the use in SLE in several countries although 
evidences of its effectiveness in LN are still lacking; prospective trials are now on-going and will shed more 
light on this topic. 
• Several other targets have been so far identified and tested at different levels of pre-clinical and clinical 
development; the more interesting are the SYK inhibitors and the anti-proteasome respectively for the 
central role of SYK in the renal manifestations of immunological diseases and for the ability of anti-
proteasome of targeting plasma-cells and therefore the main producers of auto-antibodies. 
• Combination of different targeted drugs as well as the identification of new trial designs and end-points are 
going to be key aspects of the clinical research agenda in the field of SLE and LN in the near future. 
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LUPUS NEPHRITIS AND B CELL TARGETING THERAPY 
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ABSTRACT  
Introduction: Lupus Nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE) with a significant 
prognostic impact. Over a prolonged course, an exhaustion of treatment alternatives may occur and further 
therapeutic options are needed. B cells play a pivotal role in disease pathogenesis and represent an attractive 
therapeutic target. 
Areas covered: This review provides an update regarding targeting B cell in LN. The rational for this approach, as well 
as currently available and future targets are discussed.  
Expert commentary: Despite its wide clinical use and the encouraging results from retrospective studies, a role of 
rituximab in LN has not been prospectively confirmed. Trial design methodologies as well as intrinsic limitations of this 
approach may be responsible and rituximab use is currently limited as a rescue treatment or in settings where a 
strong steroid sparing effect is warranted. Despite belimumab now being licensed for use in SLE, the evidence in LN is 
weak although prospective trials are on-going. The combination of different targeted approaches as well as a focus on 
new clinical end-points may be strategies to identify new therapeutic options. 
 
KEY WORDS:  
Auto-antibodies, Belimumab, B cell, Lupus, Lymphocytes, Nephritis, Rituximab. 
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1. INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by a wide spectrum of organ 
involvement and disease severity; renal involvement (lupus nephritis, LN) may occur in up to 40% of SLE patients (1).  
SLE glomerulonephritis is the hallmark of the immune complex disease and it is the most frequent severe 
manifestation of LN. Among all autoantibodies, anti-dsDNA plays a central role; they are in fact the most represented 
among the ones eluted from kidney biopsies (2) and may act as clinical biomarker (3). Despite this, they account for 
only 10-20% of the total auto-antibodies (2), with several others likely to play an important role including anti-C1q (4).  
As precursors of autoantibody producing cells, B cells are considered central in LN pathogenesis. However, this is only 
one of their several roles as suggested by the development of LN in a murine model carrying mutant B cells unable to 
secrete immunoglobulins while still expressing them on the surface (5); interaction with T-cells and cytokine 
production are other essential activities (6, 7). Interstitial nephritis is common in LN as unique manifestation of renal 
disease or in association with glomerulonephritis; interestingly SLE interstitial nephritis is usually characterized by an 
infiltrate rich in T and B cells sometimes organized in aggregates (8, 9) or even germinal center-like structures with 
evidence of local autoantibody production (9). Tubulointerstitial inflammation is particularly relevant in defining long-
term prognosis of LN patients and is correlated with the risk of end-stage renal disease (10) .The prompt diagnosis and 
treatment of LN has a positive impact on survival as well as on risk of end stage renal disease, however its chronic and 
relapsing course poses several challenges to the overall management.  Induction and maintenance of remission are 
key phases of the staged approach to LN and the identification of the right balance between disease activity, organ 
damage and degree of immunosuppression is central (11, 12). Corticosteroids alone are not sufficient in the treatment 
of LN and the association with immunosuppressive drugs is therefore necessary (13); although long term efficacy is 
well established for cyclophosphamide based regimen, mycophenolate mofetil has shown similar effectiveness at 
least in short and medium term trials with a more favorable adverse event profile (14).  
The availability of biologics with molecular targets is therefore of interest and among several possible targets, the B 
cell compartment has strong biological rationale. However, evidence supporting the clinical use of available B cell 
therapies in LN is lacking.  
In this paper we discuss the rationale, the current role as well as future prospective of a B cell targeted approach in 
LN. 
 
2. ANTI-CD20 APPROACH AND RITUXIMAB 
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CD20 is a B cell membrane specific antigen involved in B cell differentiation as well as B – T-cell stimulation. This 
antigen is broadly expressed by every lineage of B cells with the exception of pro-B lymphocytes and plasmacells (15).  
On the basis of the central role of B cells in SLE pathogenesis and of the results of the effectiveness of this approach in 
other autoantibody mediated diseases (16, 17), anti-CD20 antibodies have been employed in SLE. 
Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that was approved in 1997 for the treatment of Non-
Hodgkin Lymphoma with its use progressively extended to different autoimmune diseases, such as rheumatoid 
arthritis and ANCA-associated vasculitis. RTX is a type I monoclonal antibody and its action relies on the ability of 
redistributing CD20 into lipid rafts and the development of antigen-antibody complexes required to induce CD20+ B 
cell death through three mechanisms: complement dependent cytotoxicity (CDC), antibody dependent cytotoxicity 
(ADCC) and antibody-dependent cellular phagocytosis (ADCP) (18, 19). A further possible mechanism has been 
described, that involves direct cell death through activation of pro-apoptotic intracellular signaling although this 
mechanism seems more relevant for type II anti-CD20 antibodies that act without redistributing CD20 into lipid rafts 
(20, 21). The first retrospective study published in 2002 by David Isenberg's group involved six patients with SLE and 
RTX was co-administered with cyclophosphamide: a reduction of the disease activity score used (British Isles Lupus 
Assessment Group, BILAG) from 14 (range 9-27) to 6 (range 3-8) was observed as well as improvement of some 
biomarkers (overall increase of the C3 levels, in some patients reduction of the anti-dsDNA levels); in two patients 
affected by LN a reduction of the protein-to-creatinine ratio was also described (22). After this study, six retrospective 
and prospective surveys including more than fifty patients exploring the effectiveness of RTX in SLE and LN were 
identified (23-28) (Table 1). In all the studies RTX showed overall efficacy in disease control and, where explored, in 
allowing steroid sparing. The renal response was typically positive and the adverse event rate was relatively low, 
especially in the context of a population mainly characterized by a relapsing course of the disease and exposure to 
several immunosuppressive drugs. Only one study (26) reported the outcome of four patients treated with pre-
emptive multiple administrations of RTX; interestingly, no flares were observed in this population during a follow-up 
of 22 ± 9 months. A larger cohort of LN patients with relapsing or refractory disease, were studied by pooled data 
analyses of 164 patients (99 obtained via the UK-BIOGEAS registry and 65 via the review of other original articles 
already published) with LN treated with RTX: in keeping with the reports discussed in Table 1 a positive response rate 
was observed in 67% of the population at 6 and 12 months with improvements in proteinuria (4.41 g baseline vs 1.31 
g post therapy, p=0.006) and serum albumin level (28.55 g baseline vs 36.46 g post therapy, p<0.001) (29). 
The good results observed in the retrospective reports warranted prospective randomized controlled trials (RCTs) for 
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confirmation. Two main RCTs have been published in 2010 and 2012: EXPLORER and LUNAR with only the latter 
including patients with LN (30, 31). Surprisingly, both failed the primary outcome (32); Table 2 summarizes the main 
characteristics of these studies. Trials designs issues may have contributed to the negative results, especially the use 
of a background corticosteroid and immunosuppressive therapy in both arms, the selection of non-refractory cohorts, 
relatively short follow-up time, patients’ selection and no inclusion of the corticosteroid dose tapering among the 
parameters to assess the response to therapy. Despite the failure to demonstrate clinical benefit, both trials found 
RTX effective in reducing anti-dsDNA levels and improving complement levels. 
Despite the positive results of the retrospective studies and continuing physician and patient interest in the use of 
RTX, B cell depletion is currently only recommended as a rescue treatment for patients that are refractory to first and 
second line induction-maintenance approaches or in particular settings where a strong steroid sparing approach may 
be required  (28, 33). 
 
2.1 Main limitations of B cell depletion therapy with Rituximab. 
The lack of clear evidences supporting the use of RTX in SLE and LN may not only be due to issues related to trials 
design but also to intrinsic limitations of a B cell depletion approach through anti-CD20 antibodies as well as intrinsic 
SLE limitations. 
SLE has a huge variability in terms of clinical profiles and a B cell depletion approach might be effective only in specific 
subsets of the disease yet to be identified. RTX has typically been given in addition to an immunosuppressive in LN 
trials, most commonly mycophenolate mofetil. The BELONG trial (34) tested ocrelizumab in addition to either 
mycophenolate or cyclophosphamide and a larger treatment effect was noted on a cyclophosphamide background, in 
part due to a lower placebo response rate with cyclophosphamide. There are theoretical advantages to the 
combination of RTX with both mycophenolate or cyclophosphamide by targeting B cells at different levels. 
Interestingly, the combination of RTX and cyclophosphamide has shown in small studies positive results (35); although 
the safety profile does not allow a prolonged cyclophosphamide administration, the combination of these drugs at 
least in some stages might lead in subgroups of patients to advantages in the disease control. 
Moreover, B cell depletion is not selective leading to the targeting also of subsets that may be of help in controlling 
autoimmunity (such as regulatory B cells, B-regs) sparing at the same time other subsets able to produce pathogenic 
autoantibodies (namely plasmacells). 
Several studies focused on the use of RTX in autoimmune diseases have shown that the longer duration of B cell 
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depletion achieved, the better is the clinical response to the drug (36); despite also in SLE a deep depletion has been 
found as associated to clinical response (37), the proportion of patients achieving it is lower and the timing of 
repopulation quicker (38). Several factors have been considered responsible, such as, the presence or development of 
human anti-chimeric antibodies (HACAs) (39, 40) as well as differences in terms of RTX clearance (41) as a 
consequence of a different immunoglobulin metabolism.  
It should also be considered that, although we usually assess B cell depletion in the circulating compartment, this 
might not reflect what is happening in inflamed tissues. Tissue resident CD20+ B cells may be more resistant to RTX 
(42) as a consequence of a low tissue penetration of the drug or local survival factors including cell to cell contact and 
B cell stimulating cytokines; interestingly it has also been described in ABO-incompatible kidney transplant patients 
who received a single RTX infusion, that the proportion of CD19+ B cells in lymphnodes did not differ to the ones of 
untreated controls and their phenotype was more often compatible with that of switched memory B cells (IgD-
CD27+), the phenotype most represented in peripheral blood of active SLE and not detectable in SLE patients in 
remission once treated  (43, 44). 
Moreover, as already discussed, RTX is a type I monoclonal antibody and its action involves the gathering of antibody-
antigen complexes into lipid rafts of the cells: this facilitates ADCC and CDCC, but induces internalization and 
inactivation of the drug (45, 46). Internalization may also be consequence of other factors such as the surface Fc 
gamma receptor (FcgR) IIb  (47, 48).  
Many other factors have been proposed to play a role such as low complement levels and the presence of anti-C1q 
antibodies as factors impacting negatively on CDCC; moreover, the genetically determined variability of FcgR affinity 
for the Fc portions of antibodies (49, 50) as well as hypergammaglobulinemia might cause an alteration of the 
phagocytosis/ADCC through low affinity for ligand/ligand competition (20). 
Newer anti CD20 antibodies include the fully humanized type I (ocrelizumab and ofatumumab) or type II antibodies 
(obinutuzumab). For ocrelizumab a randomized controlled trial in LN (BELONG) was suspended due to excessive 
adverse events (34) although the drug seems to be effective especially in cases refractory to RTX (51), whereas for 
ofatumumab there is a limited, although positive, clinical experience on five patients with SLE and LN (52, 53) with 
further data required before its use may be considered in routine clinical practice. Regarding obinutuzumab (20), a 
randomized control trial is now running and it will provide important information regarding the feasibility and safety 
of its use in SLE (NCT02550652). Of note, both LUNAR with RTX and BELONG with ocrelizumab found similar increases 
in renal response rates of 11-12% when compared to placebo (34). These were lower than the predicted response 
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rates to show statistical superiority but of a similar order to that found in the belimumab trials, although using a 
different end-point. The latter studies had very much larger sample sizes and consequently met their end-points and 
were regarded as positive studies. 
 
3. MODULATING B CELL SURVIVAL  
A suitable alternative to B cell depletion may be the modulation of B cell survival. In SLE B cells are characterized by a 
longer lifespan, an anti-apoptotic molecular profile as well as a lower threshold for activation compared to healthy 
patients (54). Acting on factors inducing these characteristics with the aim of restoring a physiological profile may 
improve disease control. 
A central role in driving SLE B cell hyperactivity is accounted by two members of the Tumor Necrosis Factor (TNF) 
ligand superfamily (TNFSF13): the B cell Activating Factor (BAFF, also known as Blys or TNFSF13B) and A Proliferation-
Inducing Ligand (APRIL).  
BAFF and APRIL actions are mediated via three receptors: the Transmembrane Activator and Calcium-Modulator and 
Cytophilin Ligand Interactor (TACI), the B cell Maturation Antigen (BCMA) and the B cell Activating Factor Receptor 
(BR3) (55).  
B cells at different maturation stages express different receptors with TACI mainly promoting T-cell independent 
antibody responses as well as B cell regulation and immunoglobulin isotype switching, BCMA mainly promotes 
plasma-cell survival and BR3 accounts for immature B cell survival and maturation.(56) . 
The rationale for targeting these pathways is provided by the observation that both BAFF and APRIL levels are 
increased in SLE patients (57-59); moreover, mice models characterized by BAFF over-expression develop an SLE-like 
disease (60). Furthermore, BAFF levels have been consistently described as increased after B cell depletion via anti 
CD20 approaches (61, 62) and it has been described as higher in SLE patients experiencing a relapse after RTX 
administration when compared to patients who maintain disease remission (61); this has been also leading to the 
hypothesis that BAFF may play a role, at least of some degree, in limiting the effectiveness of B cell depletion. 
Whether the BAFF increase reflects simply the loss of BAFF receptors, only found on B cells, or implies a disease 
stimulating effect of RTX is unclear and there is also evidence that a high BAFF level influences the returning B cell 
repertoire towards a more autoreactive phenotype (63). 
Since the early 2000s drugs targeting BAFF and APRIL have been studied in SLE. Atacicept is a recombinant fusion 
protein including the extracellular domain of the TACI receptor joined to a human IgG1 Fc domain (64) that has been 
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tested in moderate-severe SLE in a phase II trial, this study was terminated prematurely due to safety concerns (65, 
66). Efficacy was observed in the arm treated with the higher dose of the drug tested (150 mg-arm) although the same 
group experienced two fatal infections. The on-going ADDRESS II trial (NCT02070978) might be able to shed more light 
on the possible role of this drug. A LN trial was terminated due to the occurrence of hypogammaglobulinaemia and 
infection in atacicept treated patients, when administered in addition to mycophenolate mofetil and high dose 
corticosteroid (67). 
More evidence are available for the anti-BAFF humanized monoclonal antibody belimumab: BLISS-52 and BLISS-76 are 
two large phase III multinational trials, which showed efficacy for belimumab in SLE in reducing disease activity as 
defined by the SLE responder index, a composite of disease activity scores (Table 3) (68, 69); these data found a 
favorable long-term safety profile (70) and resulted in this monoclonal antibody being the first biological drug 
approved for the use in SLE in several countries. However, the evidence for its efficacy is at the moment mainly limited 
to muscoloskeletal and mucocutaneous subsets of the disease and it is still uncertain whether it may have a role also 
in LN (71). Interestingly a post-hoc analysis of the pooled cohorts of the BLISS trial showed a signal toward a potential 
role for belimumab in improving some renal outcomes with the limitation of both trials excluding patients with acute 
renal activity at the moment of the enrollment (72). Retrospective case reports seem to support the hypothesis for a 
role of belimumab in LN (73, 74) , however it will be the BLISS-LN study (NCT01639339), a phase III randomized control 
trial, the one able to confirm this hypothesis. 
Two other anti-BAFF drugs have shown signals for a potential role in SLE: the monoclonal antibody Tabalumab and the 
fusion protein Blisibimod (75, 76). Despite a signal for the latter in terms of proteinuria reduction, both have now 
been abandoned and no further studies are ongoing at the moment.    
 
4. OTHER B CELL TARGETED THERAPY 
4.1 Modulating B cell response  
B cell receptor (BCR) signalling, as well as its intracellular transduction via second messengers, is increased in SLE (77, 
78) representing therefore a target of potential interest.  
The inhibitory transmembrane protein CD22 is a member of the immunoglobulin superfamily that recognizes sialic 
acid-containing ligands; it is expressed on different lineage of B cells with the exception of plasmablasts and 
plasmacells (79). Its mechanism of action is not fully understood but for sure it is active at different levels: following 
BCR stimulation, CD22 gets activated through a phosphorylation process mediated by Lyn, a tyrosine kinase induced 
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by BCR itself, in a feed-forward cycle (80). Once active, CD22 induces intracellular signalling resulting eventually in BCR 
dephosphorylation and inhibition (81). Interestingly, CD22 mechanisms of action appear to be various including 
indirect interaction with other intracellular signalling pathways such as the ones mediated by CD40 and Toll-like 
Receptors as well as clustering with the BCR component CD79a (82). CD22 is therefore central in setting the B cell 
threshold of activation. 
Epratuzumab is a humanised anti-CD22 monoclonal antibody that acts by inducing CD22 phosphorylation as well and 
shifting into lipid rafts, thus reducing intracellular BCR signalling. However its clinical efficacy has not been confirmed 
and the drug has been at the moment abandoned (83). Despite that, CD22 remains a target of great interest that may 
be considered for future therapeutic approaches.  
 
4.2 Targeting Intracellular pathways 
One of the main limitations of aiming for cytokines, or their receptors, is the presence of physiological mechanisms 
acting at the limitation of the “single targets approaches” such as the redundancy of the stimulus as well as the 
molecules’ internalization once bound to their cellular surface targets. Acting directly on the intracellular signals, and 
therefore on the downstream part of the activation cascade, might therefore represents a way to avoid the downsizes 
of the single target approach. 
The Bruton’s tyrosine kinase (BTK) is a key member of the BCR and FcgR signaling cascade, inducing the stimulation of 
B cell survival, differentiation as well as setting the activation threshold and inducing the antibody production (84-87). 
BTK blocking has been explored in several SLE mouse models with signals of effectiveness in terms of preventing and 
treating renal disease (88-92). 
The Spleen Tirosine Kinase (SYK) is a kinase directly activated by the Immunoreceptor tyrosine-based activation motif 
(ITAM) sequence of BCR co-receptors as well as of other immune and non-immune related receptors such as the T-cell 
receptor (TCR) and FcgR. SYK has a central pathogenic role in different autoimmune diseases and malignancies (93) as 
well as in glomerulonephritis. A retrospective study on 120 kidney biopsies of patients with glomerulonephritis 
showed that SYK expression was increased in proliferative and crescentic glomerulonephritis and correlates with the 
presenting serum creatinine as well as histological signs of disease activity; interestingly, in the subgroup of LN, SYK 
showed also a role as biomarker being higher in patients that achieved complete remission at 6 months (94). SYK 
inhibitors, such as, fostamatinib, seem an attractive and available option for autoimmune diseases in general and for 
kidney involvement of autoimmune diseases in particular (95). A role in LN has been shown in pre-clinical studies on 
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mice; interestingly, the use of this drug was not associated to reductions of anti-dsDNA titers confirming a 
downstream mechanism of action (96, 97). Data regarding fostamatinib in human SLE are not available although the 
encouraging results in terms of potential efficacy and safety in rheumatoid arthritis suggest that this is a treatment 
worth exploring (98).  
The Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) path has been recently tested in SLE and 
LN in two studies. There are four members of the JAK family and this path is particularly active in cytokine receptor 
signaling influencing DNA transcription and protein synthesis. The first study explored CP690550 showing in murine 
models improvement of proteinuria, renal function as well as histological lesions of the kidneys; interestingly a 
reduction of glomerular deposition of anti-dsDNA, of C3 and IgG was observed as well as a reduction in kidney gene 
expression of inflammatory cytokines (99). Another potential candidate acting on the JAK-STAT cascade is Tofacitininb 
characterized by promising results in terms of improvement of the nephritis in mice models (100). 
 
4.3 Modulating B-T cell interactions 
T cells play a detrimental role in driving and boosting autoimmune responses. Several reports have described 
dysfunction of the T cell compartment in SLE mainly involving Follicular Helper T cells (Tfh), Regulatory T cells and 
Th17 (101) . 
Tfh are attractive targets having a central role in conditioning germinal centers, in facilitating expansion of 
autoreactive clones and in stimulating differentiation of B cells into plasmablasts and plasmacells (102). Tfh actions 
are mediated via cytokine secretion as well as via B-T cell interactions; the latter is allowed through several co-
receptors, such as CD40-CD40L (CD154), OX40-OX40L, ICOS-ICOSL, CTLA4/CD28-CD80/CD86.  
CD40L is an important co-stimulatory molecule that is up-regulated in SLE, with higher levels of its soluble form 
described as well in this disease (103-105), and seem to correlate with disease activity in mice models (106, 107); 
moreover, a single nucleotide polymorphisms (SNP) of CD40 have been associate with disease susceptibility (108). The 
inhibition of the CD40-CD40L interaction seems a reasonable target and has proven to be effective in preventing 
disease in murine models (109, 110).  A phase II trial of a CD40L inhibitor (BG9588) in lupus nephritis showed a signal 
in terms of immunological benefit in the patients treated (reduction of the anti-dsDNA antibodies, increase of C3 
concentrations, reduction of the hematuria); however, the trial was stopped due to safety concerns related to a high 
incidence of thromboembolic events (111). This was caused by the occurrence of CD40L on platelets with Fc mediated 
platelet cross-linking caused by the therapeutic antibody. Encouraging results in terms of safety have now been 
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described with a PEGylated anti-CD40L Fab' fragment (CDP7657) from a phase I study (112, 113) suggesting that 
inhibition of this pathway remains a possible therapeutic target in SLE. An alternative is to target CD40 and this is 
being pursued by BI655064, an anti-CD40 monoclonal antibody in a Phase II LN trial (NCT02770170).  
CTLA4 is a surface molecule with inhibitory functions competing with the activating surface protein CD28 for the 
binding of CD80/86. A CTLA4-Ig (abatacept) has shown efficacy in patients with non-severe granulomatosis with 
polyangitiis (GPA) (114). The rationale for targeting this pathway in SLE has been developed from mice models where 
a CTLA4-Ig approach displayed effectiveness in preventing disease onset (115) or in reducing signs of activity in LN 
when used in combination with cyclophosphamide (116). However, despite effectiveness on anti-dsDNA and 
complement levels, no beneficial clinical effect has been so far shown (117). 
 
4.4 Proteasome inhibitors 
Proteasome inhibitors are an emerging class of drugs targeting mainly plasma-cells. Among proteasome inhibitors, 
bortezomib is the first one employed in clinical practice with indication at the moment for multiple myeloma. The 
mechanism of actions of this class of drugs is the inactivation of the Nuclear Factor kappa-light chain enhancer of 
activated B cell (NfkB) process eventually able to induce apoptosis (118). Since the high rate of protein synthesis 
typical of plasma-cells, these are very sensitive to the effects of this drug. For proteasome inhibitors also a role in 
reducing the interferon (IFN) path activation as well as IFN production has been proposed as further mechanism of 
action (119). 
Due to encouraging results for the use of bortezomib in mice models of SLE and LN (120-122) this drug has been 
tested also in humans in a study involving 12 patients with benefits in terms of reduction of the autoantibody-
producing plasma cells, IFN pathway activation and, more significantly, also in terms of clinical activity of the disease 
(123). The use of bortezomib was however associated to a reduction of protective IgG levels and necessity of 
withdrawing the treatment in seven patients due to adverse events. Interestingly, in murine models a quick 
reconstitution of the plasma cells pool have been observed once the treatment is stopped (124) and a role for co-
administration of B cell depleting treatment has been proposed as strategy for delaying plasma-cell reconstitution 
after depletion (124). An oral proteasome inhibitor, ixasomib with a more favourable safety profile is in clinical trials in 
LN (NCT02176486). 
 
5. CONCLUSIONS 
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SLE and LN are chronic diseases that often feature a long disease course with large variability in disease extent and 
severity. First and second line approaches are not infrequently exhausted in a single patient clinical history and newer 
options are required for disease management. The toxicity of current regimens and their associated serious adverse 
event rates directly worsen patient outcomes and safer therapies allowing lower corticosteroid dosing are needed. 
The targeting of B cell is supported by our understanding of pathogenesis, and RTX and belimumab have entered 
routine use in carefully defined scenarios where standard therapies are failing. The uptake of RTX has affected by the 
imbalance between positive retrospective cohort studies in largely refractory patients, and the negative results of the 
two randomised trials. Belimumab has obtained registration for use in SLE although the signals for its utility in LN are 
still weak and its role at the moment is limited to non-renal SLE; more information will be provided after a prospective 
trial in LN now ongoing (NCT01639339).  
Several targets of the B cell biology have been identified and for most of them, despite good preliminary results in 
phase II trials and pre-clinical models, no confirmation has been so far observed in phase III studies.  
 
6. EXPERT COMMENTARY  
SLE is a disease with a complex and still partially unknown biology. The success of the conventional 
immunosuppressive approaches may be due to their low specificity characterized by a widespread effect on the 
immune system; more selective approaches, although potentially of great interest and safer, may allow only partial 
benefits due to the lack of inhibition of alternative pathways not known. Based on this rationale, combining different 
biologics may allow an increase in terms of efficacy; however, such approaches need to be tested carefully considering 
concerns in terms of safety. The most obvious approach at the current stage, would be the combination use of RTX 
and belimumab: B cell depletion via RTX is in fact characterized by a rebound of BAFF levels which might explain, at 
least in some settings, the lack of efficacy. Preliminary results of subsequent therapy with RTX and belimumab are 
encouraging (125, 126) and prospective trials are now on-going (Table 4). Furthermore, RTX B cell killing will be 
potentiated by BAFF blockade. Two trials are studying this approach, CALIBRATE IN LN, and BEAT-LUPUS in non-renal 
SLE (Table 4). 
Another issue related to RTX, although potentially characteristic of other biologics as well, is that the lack of efficacy 
may be a consequence of the mode of administration. We know from experience in other autoimmune diseases that 
retreatment with RTX may improve remission rates as well as prolonging the time to relapse when compared to a 
single course of the drug although, eventually, at the drug withdrawn the relapse rate remains high (127). 
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Moreover, alternative trial designs or the definition of new end-points may facilitate demonstration of drug 
effectiveness: on average the studies published so far are designed to show a superiority or a non-inferiority of a 
tested drug compared to the standard of treatment, usually with an add-on philosophy to what considered the 
standard of care. In diseases characterized by a chronic relapsing course, frequent treatment changes or dose 
adjustments are required. In this context the efficacy of a new drug may not necessarily be shown only via a greater 
clinical benefit when added to the standard of care. Of note, clinical trials are usually characterized by a relatively 
short follow-up and an intervention that is lacking impact during the explored time spam might however unveil 
significant outcomes in the long term. In the everyday clinical life the standard of care may sometimes not be 
employed, not tolerated at full dose, refused by the patient or even ineffective. The design of classical clinical trials 
does not take into account this flexibility and may lead to the abandon of potentially useful drugs. Alternative end-
points may be taken into account in order to provide the clinical community with as many options as possible. We 
should therefore seek for non classical clinical trial designs able to overcome these limitations: examples of alternative 
strategies might include aiming at showing the ability of a new add-on treatment in allowing a quicker and aggressive 
drug sparing effect; a better clinical and safety profile in contexts where an optimal dose of the standard of care may 
not be employed; a better safety or burden of damage in longer follow-up time. Studies with different end-points may 
be characterized by more difficulties in terms of recruitment and may benefit from the use of alternative strategies of 
enrollment or treatment allocation including for example adaptive approaches. An example might be the ongoing 
RITUXILUP (Table 4) (NCT01773616) that is exploring whether the combination of RTX and mofetil mycophenolate 
(MMF) may allow sparing steroids.  
SLE is a complex disease and LN is its most severe manifestation. Research aimed at the identification of new 
therapeutic targets or biomarkers able to perform effective patient stratification is a high priority task in the research 
agenda in order to increase our therapeutic options. Moreover, alternative trials design should be developed in order 
to identify, among all the possible therapeutic targets, the ones that may have a role in the management of this 
autoimmune disease. 
 
7. FIVE YEARS VIEW 
Despite significant research efforts in the field of pathogenesis and drug development, no major changes have 
occurred in the management of LN. We do know that MMF and cyclophosphamide appear equal alternatives as first 
line approaches as induction (128) and that azathioprine, MMF, and in some settings, methotrexate may be useful for 
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the maintenance stage. Steroids are the cornerstones of the treatment, playing a central role in all phases as well as 
for the management of minor systemic flares. In this picture is now relatively well established the use of RTX as third 
line agent for both relapsing-refractory SLE and LN. Moreover belimumab is now approved for the management of SLE 
with its use mainly limited at the moment to the mucocutenous and articular manifestations. 
The studies published so far taught us that the heterogeneity of SLE manifestation and population, as well as the 
complexity of the disease, may cause difficulty in the identification of a “superiority” or of a “non-inferiority” profile 
for new drugs when compared to an optimal standard of care. We feel that in the next years the trial designs will 
switch to the identification of different end-points such as tolerability, safety and ability of a drug sparing effect for 
the treatment tested.  
The future will probably see also testing different combination of biologics and targeted therapy in order to allow a 
potential increase in efficacy of the intervention proposed. This will need to happen under strict monitoring from the 
safety point of view.  
Beside B cells, very promising are the preliminary results of targeting the interferon pathway (129, 130) but we do feel 
there may be in the short-term more interesting therapeutic options. Complement plays a central role in SLE and LN 
pathogenesis and several complement blockade molecules are now available (131). However, no trials are on-going to 
test effectiveness of this approach in SLE. Interestingly, complement is also crucial in mediating the action of several 
monoclonal antibodies and will be of great interest to see the consequences of combining anti complement drugs and 
other monoclonal antibodies.   
 
8. KEY ISSUES 
• B cells play a central role in the pathogenesis of SLE and LN therefore representing a therapeutic target of 
interest. 
• Rituximab is an anti-CD20 monoclonal antibody for which retrospective studies and clinical practice have 
shown efficacy in SLE and LN; prospective trials failed in confirming this although trial design issues, intrinsic 
limitation of both prospective studies in SLE and of an anti-CD20 approach may have had a role in these 
negative findings. 
• Belimumab is an anti BAFF monoclonal antibody registered for the use in SLE in several countries although 
evidences of its effectiveness in LN are still lacking; prospective trials are now on-going and will shed more 
light on this topic. 
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• Several other targets have been so far identified and tested at different levels of pre-clinical and clinical 
development; the more interesting are the SYK inhibitors and the anti-proteasome respectively for the 
central role of SYK in the renal manifestations of immunological diseases and for the ability of anti-
proteasome of targeting plasma-cells and therefore the main producers of auto-antibodies. 
• Combination of different targeted drugs as well as the identification of new trial designs and end-points are 
going to be key aspects of the clinical research agenda in the field of SLE and LN in the near future. 
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Table 1. Non-randomised original studies exploring the use of rituximab in SLE and LN including more than 50 patients. 
Study Type of study Therapy Follow-up Disease 
activity 
score at 
study entry 
Number 
of 
patients 
assessed 
(patients 
with LN 
%) 
Overall response 
* – timing of 
response 
assessment 
after RTX 
Renal 
response 
Steroid 
sparring 
Adverse 
events 
Relapse Response 
after re-
treatment 
with RTX * 
     
Iaccarino L. et 
Al., 2015 (2023) 
Prospective 
multicentric # 
RTX 1g two 
weeks apart, 
375mg/m
2
 for 
four weeks ^ 
with 
background 
immunosuppre
ssive 
 
 
NA ECLAM 
score – 4.11 
± 1.73 
134 (51%) 85.8% - by 12 
months 
94.1% NA 23.9% 39.5% 84.4% 
Fernandez-
Nebro A. et Al., 
2012 (2124) 
Retrospective 
multicentric 
RTX 1g two 
weeks apart, 
375mg/m2 for 
four weeks on 
average with 
background 
immunosuppre
ssive £  
26.7 
weeks 
(range, 
11.1-42.1) 
SELENA-
SLEDAI 
score -  14.6 
± 10 
116 (49%) 62.9% - 6 ±  3 
months 
65.8% From 32.4 ± 
57.3 mg/day 
to 11.7 ± 11.9 
mg/day 
42.2/100 
patients-
years 
(20.1/100 
patients-
years were 
serious) 
38.1% NA 
Aguiar R. et Al., 
2017 (2225) 
Retrospective 
monocentric 
RTX 1g two 
weeks apart 
with 500-750 
mg CYC once or 
twice and two 
administration
of 250 mg of 
methylprednis
46.03 ± 
41.10 
months 
after the 
last RTX 
cycle.   
BILAG score 
– 18.29 ± 
10.62 
115 (33%) 67% - 6 months On average, 
BILAG 
improvement 
NA 91 after first 
infusion 
NA NA 
Formatted:  Italian (Italy)
Formatted:  Italian (Italy)
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olone. 
Background 
immunosuppre
ssion was 
suspended 
until relapse. 
Terrier B. et Al., 
2010 (2326) 
Prospective 
multicentric # 
RTX 1g two 
weeks apart, 
375mg/m
2
 for 
four weeks 
with 
background 
immunosuppre
ssive  
18.6 ± 
13.8 
months 
SELENA-
SLEDAI 
score – 11.3 
± 8.9 
113 (27%)  71% - 6 ±  3 
months 
74% From 30.3 ± 
23.6 mg/day 
to 12.3 ± 10.1 
mg/day  
12%  41% 91% 
Ramos-Casals 
S. et Al., 2010 
(2427) 
Prospective 
multicentric # 
RTX 1g two 
weeks apart, 
375mg/m
2
 for 
four weeks. 
Background 
corticosteroids 
in 100% of the 
patients, 
background 
immunosuppre
ssive in 60%. 
 
 
26.05 ± 
1.62 
months 
NA 107 (46%) 77% - 12 months 79.2% Reduction of 
corticosteroid 
dose in 79% 
(withdrawal 
in 14%) 
17% 25% NA 
Condon MB et 
Al., 2013 (2528) 
Prospective 
monocentric 
RTX 1g two 
weeks apart 
with 
methylprednis
olone 500 mg 
at each 
administration. 
Maintenance 
163 weeks 
(IQR 52-
137) 
Creatinine, 
proteinuria. 
50 (100%) 86% - week 52 86%  No 
maintenance 
steroids used 
18% 22% § NA 
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with MMF & 
 
LN: lupus nephritis; CYC=cyclophosphamide; BILAG= British Isles Lupus Assessment Group ;ECLAM= European Consensus Lupus Activity Measurement ;SLEDAI= 
Systemic Lupus Erythematosus Disease Activity Index; NA: not available; MMF: mycophenolate mofetile; IQR: interquartile range. 
°: 99% of the patients received steroids, 76% of the patients received other immunesuppressive  
*: including complete and partial response according to study definition. 
#: Registry data 
ˆ: In ten cases the RTX administration was followed by two further infusions after month 1 and 2 together with two pulses of cyclophosphamide 750 mg and 
three pulses of methyilprednisolone (15 mg/Kg). 
£: no background immunosuppressive treatment in 32 patients 
&: MMF was started at the dose of 500 mg bid and then gradually titrated up to a maximum dose of 1.5 g bid. No maintenance steroidsteroids were used 
§: Renal relapses. 12% were reported to have systemic flares. 
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 Patients Inclusion criteria Treatment Major end 
points 
Results 
EXPLORER 
(Phase II-III)  
(2730) 
257 Moderate-severe disease 
activity (≥ 1 BILAG A score 
or >2 BILAG B score), 
Exclusion of CNS and renal 
involvement 
RTX 1g on days one, 
15, 168 and 182 vs 
Placebo (background 
treatment in both 
arms)* 
Response at 52 
weeks (BILAG 
score) 
Overall response rate 
28.4% (RTX arm) vs 
29.6% (placebo arm) 
(p=0.975) 
LUNAR 
(Phase III) 
(2831) 
144 Class III or class IV LN RTX 1g on days one, 
15, 168 and 182 vs 
placebo (MMF based 
background 
treatment in both 
arms)# 
Renal response 
(complete and 
partial) at 52 
weeks 
Complete renal 
response 26% RTX arm 
vs 31% placebo arm; 
Partial renal response 
31% RTX arm vs 15% 
placebo arm (p=0.55) 
 
Table 2. Randomized controlled trials of Rituximab in SLE 
BILAG= British Isles Lupus Assessment Group; CNS= Central Nervous System; LN=Lupus nephritis; RTX=Rtixumab; MMF=Mycophenolate mophetil 
*Background treatment: azathioprine 100-250 mg/day, mycophenolate mofetil 1-4 g/day, methotrexate 7.5-27.5 mg/week. Prednisone was 
administered at the dose of 0.5 mg/Kg, 0.75 mg/Kg or 1 mg/Kg according to the BILAG score. 
#Background treatment: MMF 1.5 g/day in three doses increased to 3 g/day by week four up to week 52. Intravenous methylprednisolone was 
administered two times on day one and within day three. Oral prednisone at the dose of 0.75 mg/kd/day (maximum 60 mg) was administered until 
day 16 and then tapered to ≤ 10 mg/day by week 16. 
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 PartecipantsPa
rticipants  
Inclusion 
criteria 
Treatment Major end 
points 
Results 
BLISS-52 
(phase III) 
(6269) 
867 SELENA-SLEDAI 
score >6 and a 
stable 
treatment 
regiment for a 
minimum of 1 
month. 
Exclusion of 
patients with 
lupus nephritis 
and CNS 
involvement 
1 mg/kg or 10 
mg/kg or placebo 
on days 0, 14, 28, 
thanthen every 
28 days until 48 
weeks. 
Improvement 
in SRI at week 
52.  
SRI 
improvement 
in 51, 58 and 
44% in 
belimumab 1, 
10 mg/kg and 
placebo, 
respectively 
(p=0.0006) 
BLISS-76 
(phase III) 
(6368) 
819 SELENA-SLEDAI 
score >6 and a 
stable 
treatment 
regiment for a 
minimum of 1 
month. 
Exclusion of 
patients with 
lupus nephritis 
and CNS 
involvement 
1 mg/kg or 10 
mg/kg or placebo 
on days 0, 14, 28, 
thanthen every 
28 days until 72 
weeks. 
Improvement 
in SRI at week 
76.  
SRI 
improvement 
in 40.6, 43.2, 
33.5% in 
belimumab 1, 
10 mg/kg and 
placebo, 
respectively 
(p=0.089 and 
p=0.017) 
Table 3. Main Randomized Controlled Trials of Belimumab in SLE 
SELENA-SLEDAI= SELENA-SLE Disease Activity Index; SRI= Systemic Lupus Erythematosus Responder Index; 
CNS=Central Nervous System 
 
 
Formatted: English (U.K.)
Page 49 of 52
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Table 4. On-going clinical trials in lupus nephritis employing biologics drugs. 
 
Target Drug Trial - ID Type of study Phase Primary Outcome 
CD20 
 
Rituximab  RITUXILUP -  
NCT01773616 
Randomized: 
rituximab + IV MP + 
MMF vs oral 
prednisolone + IV MP 
+ MMF  
III Non-inferiority of rituximab vs control in the 
proportion of patients achieving complete renal 
response at week 52 without the need of steroid 
prescription. 
Rituximab RING -  NCT01673295 Randomized: 
rituximab + standard 
of care vs standard of 
care 
III Percentage of patients achieving renal complete 
response at 104 weeks. 
Obinutuzumab NA -  NCT02550652 Randomized: 
obinutuzumab  + 
MMF vs placebo + 
MMF 
II Percentage of patients who achieve complete 
renal response at week 52. 
BAFF 
 
Belimumab BLISS-LN -  
NCT01639339 
Randomized: 
belimumab + standard 
of therapy vs placebo 
+ standard of therapy 
III Number of patients with a renal response at week 
104. 
Blisibimod CHABLIS 7.5 -  
NCT02514967 
 
Randomized: 
blisibimod + standard 
of care vs placebo + 
blisibimodstandard of 
care 
III Proportion of the responders to the SRI-6 
composite responder index at week 52. 
CD20 and BAFF 
 
Rituximab - 
belimumab 
CALIBRATE -  
NCT02260934 
Randomized: 
rituximab + 
cyclophosphamide + 
IV 
II Proportion of patients experiencing at least one 
grade 3 or higher infectious adverse events up to 
week 48. 
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methylprednisolone + 
oral prednisone vs 
rituximab + 
cyclophosphamide + 
IV 
methyliprednisolone + 
oral prednisone + 
belimumab 
Rituximab and 
belimumab.  
SYNBIoSe -  
NCT02284984 
Non randomized II  Reduction of pathogenetic autoantibodies 
IFN α/β 
receptor 
Anifrolumab TULIP-LN1 -  
NCT02547922 
Randomized: 
anifrolumab at 2 
different doses + 
standard of care vs 
placebo + standard of 
care 
II Relative difference in change from baseline to 52 
week proteinuria  
Proteasome Ixazomib NA -  NCT02176486 Randomized: 
Ixazomib at different 
doses + standard of 
care vs placebo + 
standard of care 
I Safety up to 28 weeks (Emergent Adverse Event, 
Serious Adverse Events) 
CD40 BI 655064 NA -  NCT02770170 Randomized: BI 
655064 at 3 different 
doses + standard of 
care vs placebo + 
standard of care 
II Proportion of patients with complete renal 
response at 52 weeks. 
NFkB Iguratimod NA -  NCT02936375 Randomized: 
Iguratimod + steroids 
vs cyclophosphamide 
followed by 
azathioprine + 
steroids 
II Renal remission rate at week 52. 
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CD74 Milatuzumab NA -  NCT01845740 Randomized: 
Milatuzumab at 2 
different doses vs 
placebo *  
I-II Safety and efficacy (variation of BILAG score) up to 
2 years. 
 
RTX=rituximab; CYC=cyclphosphamide; MMF= mycophenolate mophetil; BCDT= B cell Depleting therapy; CR= Complete Response; LN=lupus 
nephritis; SOC= standard of care; AZA= azathioprine 
* not specified if added to standard of care. 
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